Literature DB >> 2646738

Current considerations in the management of neoplastic spinal cord compression.

T Siegal1, T Siegal1.   

Abstract

Nearly 20% of patients with neoplastic involvement of the vertebral column develop spinal cord compression, and in 8% this is the initial manifestation of cancer. Important determinants of functional prognosis are: 1) tumor biology, 2) pretreatment neurologic status, and 3) tumor location within the spinal canal and the therapy employed. Future efforts should be invested in manipulation of the last two determinants. Delay in neurologic deterioration may be achieved by pharmacologic manipulation of the deleterious pathophysiologic processes operating in the compressed spinal cord, as recently demonstrated in experimental animal models. Use of modern neuro-imaging techniques (metrizamide myelography combined with computed tomography, and/or magnetic resonance imaging) will accurately define tumor extent and location. Radiotherapy is indicated in highly or moderately radiosensitive tumors. Surgery is reserved for the following situations: diagnosis in doubt, previous radiation exposure, radioresistant tumors, neurologic deterioration during irradiation, and the presence of spinal instability or bone compression of the neural structures. The location of the compressing tumor will dictate the surgical approach--a vertebral body resection in an anterior or anterolateral tumor and a laminectomy in a posterior or posterolateral deposit. Modern instrumentation techniques for spinal column stabilization or vertebral body replacement will allow immediate painless ambulation and a better quality of life for these patients.

Entities:  

Mesh:

Year:  1989        PMID: 2646738     DOI: 10.1097/00007632-198902000-00015

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  14 in total

1.  Surgical management of vertebral neoplasia: who, when, how and why?

Authors:  S J Krikler; D S Marks; A G Thompson; W F Merriam; D Spooner
Journal:  Eur Spine J       Date:  1994       Impact factor: 3.134

2.  Operative management of epidural tumors of the spine.

Authors:  J D Rompe; C Hopf; J Heine
Journal:  Arch Orthop Trauma Surg       Date:  1994       Impact factor: 3.067

3.  Metastatic spinal cord compression--options for surgical treatment.

Authors:  J D Rompe; P Eysel; C Hopf; J Heine
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

4.  Palliative considerations in the surgical treatment of spinal metastases: evaluation of posterolateral decompression combined with posterior instrumentation.

Authors:  Jan Walter; Rupert Reichart; Albrecht Waschke; Rolf Kalff; Christian Ewald
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-30       Impact factor: 4.553

Review 5.  The treatment of spinal metastases.

Authors:  Karl-Stefan Delank; Clemens Wendtner; Hans Theodor Eich; Peer Eysel
Journal:  Dtsch Arztebl Int       Date:  2011-02-04       Impact factor: 5.594

6.  Sciatica as a presenting feature of thyroid follicular adenocarcinoma in a 79-year-old woman.

Authors:  Elisha Ogbodo; Chandrasekaran Kaliaperumal; Catherine Keohane; Niamh Bermingham; George Kaar
Journal:  BMJ Case Rep       Date:  2011-12-01

7.  Prognostic factors in anterior decompression for metastatic cord compression. An analysis of results.

Authors:  E Sucher; J Y Margulies; Y Floman; G C Robin
Journal:  Eur Spine J       Date:  1994       Impact factor: 3.134

Review 8.  Metastatic Complications of Cancer Involving the Central and Peripheral Nervous Systems.

Authors:  Joe S Mendez; Lisa M DeAngelis
Journal:  Neurol Clin       Date:  2018-06-15       Impact factor: 3.806

Review 9.  Spinal metastasis in the elderly.

Authors:  Max Aebi
Journal:  Eur Spine J       Date:  2003-09-23       Impact factor: 3.134

10.  Is surgery for spine metastasis reasonable in patients older than 60 years?

Authors:  Tangzhao Liang; Yong Wan; Xuenong Zou; Xinsheng Peng; Shaoyu Liu
Journal:  Clin Orthop Relat Res       Date:  2012-11-21       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.